Abstract:Built on coercive reciprocity, the EU’s International Procurement Instrument (IPI) Regulation incorporates economic security objectives into trade policy. It seeks to compel third countries to open their procurement markets and create what it describes as a level playing field for EU firms. In April 2024, the European Commission launched its first investigation under the IPI into China’s public procurement market for medical devices, based on its preliminary assessment that Chinese policies systematically restricted access for EU firms. In October 2024, the Court of Justice of the European Union ruled in a public procurement dispute that firms from countries covered by neither the WTO Agreement on Government Procurement (GPA) nor other relevant procurement agreements with the EU cannot claim equal treatment in EU public procurement. The ruling highlights the dual character of IPI enforcement: the use of public procurement as an instrument of strategic competition, and the limited scope for economic operators from third countries without such agreements to claim equal treatment under EU procurement directives. The IPI has increased compliance costs and investment uncertainty for Chinese firms and will further exacerbate EU-China economic and trade frictions and disrupt the multilateral trading system. These challenges call for a response at both the firm and government levels. Firms should strengthen compliance and mitigate risks, while the government should deepen its engagement in institutional bargaining and strengthen its capacity to adopt countermeasures.